Xarelto Denied by Insurance? How to Appeal

Xarelto (rivaroxaban) is one of the most prescribed anticoagulants worldwide, approved for atrial fibrillation, DVT/PE treatment, cardiovascular event prevention, and more. Despite strong clinical evidence, it's frequently denied in favor of cheaper warfarin. Here's how to fight back.

Xarelto FDA-Approved Indications

Rivaroxaban (Xarelto) has one of the broadest FDA approval profiles among DOACs:

1. Non-valvular atrial fibrillation (AFib): Reduce risk of stroke and systemic embolism
2. DVT treatment: Active deep vein thrombosis
3. PE treatment: Active pulmonary embolism
4. DVT/PE prophylaxis: Reduce risk of recurrent DVT/PE after initial treatment
5. Post-surgical VTE prophylaxis: After elective hip or knee replacement surgery
6. Medically ill patients: VTE prophylaxis in hospitalized acutely ill medical patients
7. CAD/PAD: Reduce risk of cardiovascular events in patients with chronic CAD or PAD (combined with aspirin — VOYAGER PAD and COMPASS trials)

Why Insurers Deny Xarelto

Warfarin step therapy. Like other DOACs, Xarelto is denied when plans require warfarin trial first. The arguments against this are identical to those for Eliquis — warfarin has a narrower therapeutic index, requires frequent INR monitoring, and has more drug/food interactions.

Formulary preference for Eliquis. Eliquis (apixaban) has become formulary-preferred on many plans due to its once-daily dosing and bleeding profile. A formulary exception for Xarelto may be needed if your cardiologist/hematologist has a specific clinical rationale.

Indication-specific PA requirements. The COMPASS/VOYAGER indications (CAD/PAD + aspirin) are less commonly covered and may face skepticism from plans unfamiliar with this newer indication.

Once-daily dosing advantage. Xarelto for AFib is dosed once daily (most other DOACs twice daily) — a significant adherence advantage for some patients that can be argued in an appeal.

Clinical Evidence for Xarelto

ROCKET AF Trial (NEJM 2011) — AFib

Xarelto vs. warfarin in 14,264 AFib patients (the largest DOAC trial at the time):

• Non-inferior to warfarin for stroke and systemic embolism prevention
• Significant reduction in intracranial and fatal hemorrhage vs. warfarin
• Once-daily dosing advantage for adherence

EINSTEIN Trials — DVT/PE

EINSTEIN-DVT and EINSTEIN-PE: Xarelto vs. standard therapy (enoxaparin + warfarin) for acute DVT/PE:

• Non-inferior efficacy for recurrent VTE prevention
• Significantly less major bleeding (EINSTEIN-PE: HR 0.49, p=0.003)
• Simplified single-drug treatment — no bridging therapy needed

COMPASS Trial — CAD/PAD

Xarelto 2.5 mg twice daily + aspirin 100 mg vs. aspirin alone in stable CAD/PAD:

• 24% relative risk reduction in MACE (cardiovascular death, stroke, MI)
• Significant reduction in stroke (by 42%)
• Modest increase in major bleeding (but not fatal bleeding)
• Led to FDA approval for cardiovascular risk reduction in CAD/PAD

VOYAGER PAD Trial — PAD Post-Revascularization

Xarelto 2.5 mg twice daily + aspirin after lower extremity revascularization:

• 15% relative risk reduction in MALE (major adverse limb events) and MACE

Building Your Appeal

Step 1: Identify the Specific Indication

Xarelto's appeal arguments differ by indication. Make sure the PA request clearly specifies:

• AFib: CHA₂DS₂-VASc score, non-valvular AFib diagnosis
• DVT/PE: Active VTE diagnosis, imaging confirmation
• CAD/PAD: Documented stable CAD or PAD, aspirin co-administration
• Post-surgical: Surgery type (hip or knee), timing

Step 2: Document Warfarin Inappropriateness

For AFib/VTE indications:

• History of labile INR on warfarin (TTR <65%)
• Inability to comply with weekly INR monitoring (work, mobility, caregiver constraints)
• Drug interactions with warfarin (amiodarone, antibiotics, antifungals)
• Dietary restrictions interfering with warfarin (INR instability with diet)
• History of significant bleeding on warfarin
• Patient preference for simplified monitoring (important for quality-of-life arguments)

Step 3: Cite AHA/ACC Guidelines

2023 ACC/AHA AFib Guidelines: DOACs preferred over warfarin for non-valvular AFib (Class I, Level A). Xarelto is specifically listed as an approved DOAC option.

AHA/ACC ROCKET AF Analysis: Once-daily dosing of Xarelto vs. twice-daily dosing of other DOACs may confer adherence benefits — relevant for patients with demonstrated difficulty with twice-daily dosing.

Step 4: COMPASS Indication

For the COMPASS indication (CAD + aspirin), this is a relatively new approved use. Cite:

• COMPASS trial publication (NEJM 2017)
• FDA approval date (2018) for this indication
• AHA/ACC peripheral artery disease guidelines recommending Xarelto + aspirin

Step 5: Request Peer-to-Peer Review

A cardiologist-to-cardiologist or hematologist call specifically addressing the clinical rationale resolves most DOAC denials.

Formulary Exception Between Xarelto and Eliquis

If your plan prefers Eliquis and you're on Xarelto (or vice versa):

• Document prior failure or intolerance of the formulary-preferred DOAC
• If switching from Xarelto to Eliquis: document any bleeding history, adherence concerns with twice-daily dosing
• Physician preference with explicit clinical rationale is a valid basis for formulary exception

Sample Appeal Language

"I am appealing the denial of Xarelto (rivaroxaban) [dose] for [non-valvular atrial fibrillation / DVT/PE treatment / CAD with aspirin]. My cardiologist/hematologist, Dr. [Name], has determined that Xarelto is the medically appropriate anticoagulant therapy for this patient.

[For AFib:] 2023 ACC/AHA Guidelines recommend DOACs over warfarin for non-valvular AFib (Class I, Level A). Warfarin is clinically inappropriate for this patient due to [reason]. [For CAD:] COMPASS trial demonstrated a 24% relative risk reduction in MACE with Xarelto + aspirin (FDA-approved 2018). Requiring alternative therapy conflicts with established evidence-based guidelines. I respectfully request reversal of this denial."

Fight Back With ClaimBack

ClaimBack generates Xarelto appeal letters citing ROCKET AF / EINSTEIN / COMPASS trial data, ACC/AHA guideline recommendations, and warfarin inappropriateness arguments.

Free analysis. Appeal letter from USD 12.

Related Reading

• Prior Authorization Denied: How to Appeal" class="auto-link">Prior Authorization Denied? How to Appeal
• What Is Medical Necessity and How to Prove It
• Common Reasons Insurance Claims Are Denied